The primary objective of this study is to determine the recommended phase II dose (RP2D) and schedule of CX-4945 in patients with locally advanced or metastatic basal cell carcinoma (BCC).
Secondary Objective
To establish the safety and tolerability of CX-4945 in this patient population.
To assess preliminary evidence of antitumor effects in this patient population by documentation of objective responses using standardized criteria.
To evaluate the effect of CX-4945 treatment on the Hh signaling pathway using qRT-PCR in fresh-frozen tissue from patients with locally advanced BCC obtained at baseline and following CX-4945 treatment.
